JAK-STAT inhibitors in noninfectious uveitis – A review
Indian Journal of Ophthalmology · 2025-06 · 73 (6) · 807-815
DOI: 10.4103/ijo.ijo_61_25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 28.05.2025. Verfasst von Richa Pyare und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Retina and Uvea, Shroff Eye Centre, New Delhi, India. Hauptthemen laut MEDLINE: Uveitis, Janus Kinase Inhibitors, STAT Transcription Factors, Janus Kinases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
The management of noninfectious uveitis (NIU) has involved the use of corticosteroids and immunomodulators (IMT). However, a certain subset of NIU patients does not respond to conventional IMT therapy, such as methotrexate and azathioprine. In these patients, biological IMT with specific targets is employed. One such example is the use of TNF-α inhibitors, such as adalimumab and infliximab. These biologics target specific inflammatory cytokines, unlike the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. JAK-STAT inhibitors (JAKinibs) are classified as targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), which are small-molecule drugs that are chemically synthesized rather than biologically derived. In contrast to biologic DMARDs or bDMARDs, tsDMARDs are smaller molecules that are orally available, nonimmunogenic, and capable of crossing the cell membrane. JAKinibs can simultaneously block multiple cytokine-signalling pathways, such as those driven by IL-6, IL-12, IL-23 and IL-17, as they dampen Th1- and Th17-driven inflammation. This ability to target a broad range of inflammatory cytokines and immune pathways theoretically enables JAKinibs to be viable alternatives for the treatment of NIU resistant to conventional IMT and biologicals. JAK-STAT inhibitors, such as tofacitinib, baricitinib, upadacitinib, peficitinib, delgocitinib, and filgotinib have been FDA-approved for use in autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and inflammatory bowel disease. The available literature suggests the potential efficacy of these drugs in controlling uveitic inflammation; however, their use in NIU is still under investigation, with no randomized controlled trials providing Level I evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Retina and Uvea, Shroff Eye Centre, New Delhi, India.
- Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
- Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, College Road, Chennai, Tamil Nadu, India.
- Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
- Department of Clinical Immunology and Rheumatology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, Tamil Nadu, India.
- Department of Paediatric Rheumatology Bristol Royal Hospital 55 for Children and Translational Health Sciences, University of Bristol, 56 Bristol, UK.
Zitieren
APA
Pyare, R., Shaikh, N., Sen, A., Kene, R., Bagri, N., Janarthanan, M., Chawla, R., Ramanan, A. V., & Dutta Majumder, P. (2025). JAK-STAT inhibitors in noninfectious uveitis – A review. Indian Journal of Ophthalmology, 73(6), 807-815. https://doi.org/10.4103/ijo.ijo_61_25
Vancouver
Pyare R, Shaikh N, Sen A, Kene R, Bagri N, Janarthanan M, et al. JAK-STAT inhibitors in noninfectious uveitis – A review. Indian Journal of Ophthalmology. 2025;73(6):807-815. doi:10.4103/ijo.ijo_61_25
BibTeX
@article{Pyare2025,
author = {Pyare, Richa and Shaikh, Nawazish and Sen, Ahana and Kene, Rakshita and Bagri, Narendra and Janarthanan, Mahesh and Chawla, Rohan and Ramanan, Athimalaipet V and Dutta Majumder, Parthopratim},
title = {JAK-STAT inhibitors in noninfectious uveitis – A review},
journal = {Indian Journal of Ophthalmology},
year = {2025},
volume = {73},
number = {6},
pages = {807--815},
doi = {10.4103/ijo.ijo_61_25}
}
EUVIMED